Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients

被引：0
|
作者：
Saam A. Mojtahed
Nicole R. Boyer
Saieesh A. Rao
Thomas F. Gajewski
Jennifer Tseng
Kiran K. Turaga
机构：
[1] University of Chicago,Pritzker School of Medicine, Division of Biological Sciences
[2] University of Chicago,Center for Health and the Social Sciences
[3] University of Chicago,Department of Pathology, Division of Biological Sciences
[4] The University of Chicago,Department of Surgery, Division of Biological Sciences
来源：
Annals of Surgical Oncology | 2021年 / 28卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：9039 / 9047
页数：8
相关论文
共 50 条
  • [21] Adjuvant FOLFIRINOX in Patients with Resected Pancreatic Ductal Adenocarcinoma: A Cost-effectiveness Analysis
    Hersh, A. R.
    Buuck, T.
    Wagner, J.
    Kardosh, A.
    Caughey, A.
    Mayo, S. C.
    Billingsley, K. G.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S45 - S45
  • [22] Cost-effectiveness of adjuvant chemotherapy with uracil-tegafur for curatively resected stage III rectal cancer
    Hisashige, A.
    Yoshida, S.
    Kodaira, S.
    BRITISH JOURNAL OF CANCER, 2008, 99 (08) : 1232 - 1238
  • [23] Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain
    González-Larriba, JL
    Serrano, S
    Alvarez-Mon, M
    Camacho, F
    Casado, MA
    Díaz-Pérez, JL
    Díaz-Rubio, E
    Fosbrook, L
    Guillem, V
    López-López, JJ
    Moreno-Nogueira, JA
    Toribio, J
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (18) : 2344 - 2352
  • [24] Cost-Effectiveness of PET/CT Surveillance Schedules to Detect Distant Recurrence of Resected Stage III Melanoma
    Dieng, Mbathio
    Turner, Robin M.
    Lord, Sarah J.
    Einstein, Andrew J.
    Menzies, Alexander M.
    Saw, Robyn P. M.
    Nieweg, Omgo E.
    Thompson, John F.
    Morton, Rachael L.
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (04)
  • [25] Cost-effectiveness of interferon for high-risk (stage III) melanoma patients
    Guillem, V
    Alvarez-Mon, M
    Camacho, F
    Diaz-Perez, JL
    Diaz-Rubio, E
    Gonzalez-Larriba, JL
    Lopez-Lopez, JJ
    Moreno, JA
    Serrano, S
    Toribio, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S372 - S372
  • [26] COST-EFFECTIVENESS ANALYSIS OF OXLIPLATIN IN ADJUVANT THERAPY FOR STAGE 3 COLON CANCER PATIENTS IN JAPAN
    Fukuda, T.
    Shiroiwa, T.
    Takeuchi, T.
    Shimozuma, K.
    Ohashi, Y.
    VALUE IN HEALTH, 2010, 13 (07) : A266 - A266
  • [27] Should Targeted Therapy Be Continued in BRAF-Mutant Melanoma Patients after Complete Remission?
    Bedouelle, Eve
    Nguyen, Jean Michel
    Varey, Emilie
    Khammari, Amir
    Dreno, Brigitte
    DERMATOLOGY, 2022, 238 (03) : 517 - 526
  • [28] Cost-effectiveness analysis of PET/CT surveillance imaging to detect systemic recurrence in resected stage III melanoma: study protocol
    Dieng, Mbathio
    Khanna, Nikita
    Nguyen, Mai Thi Hoang
    Turner, Robin
    Lord, Sarah J.
    Menzies, Alexander M.
    Allen, Jay
    Saw, Robyn
    Nieweg, Omgo E.
    Thompson, John
    Morton, Rachael L.
    BMJ OPEN, 2020, 10 (11):
  • [29] Adjuvant chemotherapy in patients with resectable stage III colon cancer: lifetime cost-effectiveness and cost-utility analysis
    Bonistalli, L
    Bardelli, F
    Costantini, M
    Trallori, G
    d'Albasio, G
    Messori, A
    CANCER JOURNAL - FRANCE, 1998, 11 (01): : 39 - 47
  • [30] Targeted Therapy for the Adjuvant Treatment of Stage III BRAF-Mutated Melanoma
    Long, Georgina
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (01) : 25 - 27
12345